Ivor Royston - 17 Mar 2022 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role: CEO & President, Director
Signature: /s/ Daniel Chevallard, as Attorney-in-Fact
Issuer symbol: VIRX
Transactions as of: 17 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 18 Mar 2022, 17:32:39 UTC
Previous filing: 01 Mar 2022
Next filing: 27 May 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIRX	Stock Option (Right to Buy)	Award	$0	+412,500		$0.000000	412,500	17 Mar 2022	Common Stock	412,500	$3.04	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One forty-eighth (1/48th) of the shares subject to the option shall vest on the date one month following February 23, 2022 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date.

Content

One forty-eighth (1/48th) of the shares subject to the option shall vest on the date one month following February 23, 2022 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date.